Autoimmune Diseases

Systemic Lupus Erythematosus


Publishing date
21 Sep 2012
Status
Published
Submission deadline
04 May 2012

Lead Editor

1Minami-Otsuka Institute of Technology, Minami-Otsuka Clinic, 2-41-9 Minami-Otsuka, Toshima-ku, Tokyo 170-0005 Japan

2Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain

3Division of Rheumatology and Clinical Immunology, School of Medicine, Jichi Medical University, 3311 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan

4Faculty of Biomedical Engineering, Toin University of Yokohama, 1614 Kurogane-machi, Aoba-ku, Yokohama 225-8802, Japan

5Department of Immunology and Rheumatology, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Vasco de Quiroga 15, Colonia Sección XVI, 14000 Mexico City, DF, Mexico


Systemic Lupus Erythematosus

Description

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by widespread immunologic abnormalities and multiorgan involvement including the skin, joints, and the peripheral and central nervous systems, amongst other organs and systems. The clinical course of SLE is usually dependent on the organ involved such as neuropsychiatric syndromes of systemic lupus erythematosus (NPSLE), lupus nephritis (LN), lupus pancreatitis (LP), and pulmonary hypertension (PH). Early diagnosis and epoch-making therapeutic strategies are prerequisites for improved prognosis of patients with SLE. To fulfill this medical need, a better understanding of the pathogenesis of SLE is required. Research over the course of several years has yielded a basic scientific understanding of SLE pathogenesis. This includes understanding the role of various cytokines and chemokines in disease progression, the chronic activation of plasmacytoid dendritic cells by circulating immune complexes, and the expression of neutrophil-specific genes.

The main focus of this special issue will be on the diagnostic tools for specific organ involvement in SLE (NPSLE, LN, LP, PH, etc.) and on the development of new therapeutic strategies (biologics, etc.), as well as the pathogenesis of SLE, including animal models of SLE. This special issue will become an international forum for researchers and clinicians to summarize the most recent developments and ideas in the field.

We invite investigators to contribute original research as well as review articles. Potential topics include, but are not limited to:

  • Immunological pathogenesis of lupus: roles of activation of plasmacytoid dendritic cells by circulating immune complex NKT cells, invariant NKT cells, autoantibodies, and autoantigens in the pathogenesis of lupus
  • Early diagnostic tools for NPSLE, LN, LP, and PH: intrathecal cytokines, chemokines, and autoantibodies
  • Therapeutic strategies for lupus: immunosuppressants (cyclophosphamide and mycophenolate mofetil (MMF)), biologics (anti-CD20 antibody and BLyS-specific inhibitor), and so forth
  • Genetic approach in the pathogenesis of lupus and murine models for lupus: MHC genes, genes encoding complement components, TNF, FcγR, T cell receptors, and cytokines

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ad/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2012
  • - Article ID 815753
  • - Editorial

Systemic Lupus Erythematosus

Hiroshi Okamoto | Ricard Cervera | ... | Taku Yoshio
  • Special Issue
  • - Volume 2012
  • - Article ID 814048
  • - Research Article

A Novel Method for Real-Time, Continuous, Fluorescence-Based Analysis of Anti-DNA Abzyme Activity in Systemic Lupus

Michelle F. Cavallo | Anna M. Kats | ... | Mirjana Pavlovic
  • Special Issue
  • - Volume 2012
  • - Article ID 683829
  • - Research Article

Role of Structure-Based Changes due to Somatic Mutation in Highly Homologous DNA-Binding and DNA-Hydrolyzing Autoantibodies Exemplified by A23P Substitution in the VH Domain

A. V. Kozyr | A. V. Kolesnikov | ... | A. G. Gabibov
  • Special Issue
  • - Volume 2012
  • - Article ID 812138
  • - Clinical Study

Screening Tests of Reproductive Immunology in Systemic Lupus Erythematosus

Zdenka Ulcova-Gallova | Alice Mockova | Miroslava Cedikova
  • Special Issue
  • - Volume 2012
  • - Article ID 321614
  • - Review Article

Evaluation of ENA-6 Profile by ELISA Immunoassay in Patients with Systemic Lupus Erythematodes

Izeta Aganovic-Musinovic | Jasenko Karamehic | ... | Suvada Svrakic
  • Special Issue
  • - Volume 2012
  • - Article ID 589359
  • - Review Article

Intravenous Immunoglobulin in the Management of Lupus Nephritis

Scott E. Wenderfer | Trisha Thacker
  • Special Issue
  • - Volume 2012
  • - Article ID 819634
  • - Research Article

Multiple Autoantibodies Display Association with Lymphopenia, Proteinuria, and Cellular Casts in a Large, Ethnically Diverse SLE Patient Cohort

Rufei Lu | Julie M. Robertson | ... | Judith A. James
  • Special Issue
  • - Volume 2012
  • - Article ID 301274
  • - Review Article

Neonatal Lupus Erythematosus

Kam Lun Hon | Alexander K. C. Leung
  • Special Issue
  • - Volume 2012
  • - Article ID 876456
  • - Review Article

Vascular Disease in Systemic Lupus Erythematosus

Athina Pyrpasopoulou | Sofia Chatzimichailidou | Spyros Aslanidis
  • Special Issue
  • - Volume 2012
  • - Article ID 725249
  • - Review Article

Osteonecrosis in Systemic Lupus Erythematosus: An Early, Frequent, and Not Always Symptomatic Complication

Paola Caramaschi | Domenico Biasi | ... | Silvano Adami
Autoimmune Diseases
 Journal metrics
See full report
Acceptance rate-
Submission to final decision-
Acceptance to publication-
CiteScore4.600
Journal Citation Indicator0.400
Impact Factor4.0
 Submit Check your manuscript for errors before submitting

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.